BACKGROUND: Dose intensification is a common approach to treat Crohn's disease (CD) patients who lose response to infliximab maintenance therapy. Few studies have reported upon its long-term efficacy or predictors of response. AIM: The goal of this study is to investigate durability and predictors of response to dose intensification-including method of dose intensification, combination immunomodulator therapy, and premedication with intravenous hydrocortisone. METHODS: We performed a retrospective study of dose-intensified CD patients at our institution. Dose intensification was defined as an increase in dose from 5 to 10 mg/kg, an increase in frequency of infusions from every 8 weeks to every 6 weeks or less, or both an increase in dose and frequency. RESULTS: Thirty CD patients (mean age, 39.9 years) met study criteria and underwent dose intensification. Ten (33.3%) patients remained on dose intensification at the end of our study or returned to their former infliximab dose or schedule (median follow-up, 41 months). Fourteen patients (46.7%) eventually lost response to dose intensification, but dose intensification extended infliximab therapy by a median duration of 9 months. Six patients (20%) didn't respond to dose intensification. Neither method of dose intensification, combination immunomodulator therapy, nor premedication with intravenous hydrocortisone predicted initial or durable response to dose intensification. However, analysis of predictors was limited by the small sample size of our study. CONCLUSIONS: The majority of CD patients respond to dose intensification, and a substantial portion will experience durable response such that infliximab therapy is successfully extended by one or more years.
BACKGROUND: Dose intensification is a common approach to treat Crohn's disease (CD) patients who lose response to infliximab maintenance therapy. Few studies have reported upon its long-term efficacy or predictors of response. AIM: The goal of this study is to investigate durability and predictors of response to dose intensification-including method of dose intensification, combination immunomodulator therapy, and premedication with intravenous hydrocortisone. METHODS: We performed a retrospective study of dose-intensified CDpatients at our institution. Dose intensification was defined as an increase in dose from 5 to 10 mg/kg, an increase in frequency of infusions from every 8 weeks to every 6 weeks or less, or both an increase in dose and frequency. RESULTS: Thirty CDpatients (mean age, 39.9 years) met study criteria and underwent dose intensification. Ten (33.3%) patients remained on dose intensification at the end of our study or returned to their former infliximab dose or schedule (median follow-up, 41 months). Fourteen patients (46.7%) eventually lost response to dose intensification, but dose intensification extended infliximab therapy by a median duration of 9 months. Six patients (20%) didn't respond to dose intensification. Neither method of dose intensification, combination immunomodulator therapy, nor premedication with intravenous hydrocortisone predicted initial or durable response to dose intensification. However, analysis of predictors was limited by the small sample size of our study. CONCLUSIONS: The majority of CDpatients respond to dose intensification, and a substantial portion will experience durable response such that infliximab therapy is successfully extended by one or more years.
Authors: Richard J Farrell; Mazen Alsahli; Yoon-Tae Jeen; Kenneth R Falchuk; Mark A Peppercorn; Pierre Michetti Journal: Gastroenterology Date: 2003-04 Impact factor: 22.682
Authors: Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts Journal: N Engl J Med Date: 2003-02-13 Impact factor: 91.245
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: M Allez; S Vermeire; N Mozziconacci; P Michetti; D Laharie; E Louis; M-A Bigard; X Hébuterne; X Treton; A Kohn; P Marteau; A Cortot; C Nichita; G van Assche; P Rutgeerts; M Lémann; J-F Colombel Journal: Aliment Pharmacol Ther Date: 2010-01 Impact factor: 8.171
Authors: Mahboob U Rahman; Ingrid Strusberg; Piet Geusens; Alberto Berman; David Yocum; Daniel Baker; Carrie Wagner; John Han; Rene Westhovens Journal: Ann Rheum Dis Date: 2007-03-28 Impact factor: 19.103
Authors: Ashish Srinivasan; Robert Gilmore; Daniel van Langenberg; Peter De Cruz Journal: Therap Adv Gastroenterol Date: 2022-02-02 Impact factor: 4.409
Authors: Chamaida Plasencia; Teresa Jurado; Alejandro Villalba; Diana Peitedado; Maria Teresa López Casla; Laura Nuño; María Gema Bonilla; Ana Martínez-Feito; Emilio Martín-Mola; Dora Pascual-Salcedo; Alejandro Balsa Journal: Front Med (Lausanne) Date: 2015-10-08